These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 20676796)

  • 21. [Factors influencing secondary prevention of atherothrombotic disease in the private outpatient cardiology setting: results of the Prisma survey].
    Cambou JP; Ferrieres J; Grenier O; Boka G; Cantet C; Leizorovicz A
    Ann Cardiol Angeiol (Paris); 2003 Feb; 52(1):20-9. PubMed ID: 12710291
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimal secondary prevention medication use in acute myocardial infarction patients with nonobstructive coronary artery disease is modified by management strategy: insights from the TRIUMPH Registry.
    Pitts R; Daugherty SL; Tang F; Jones P; Ho PM; Tsai TT; Spertus J; Maddox TM
    Clin Cardiol; 2017 Jun; 40(6):347-355. PubMed ID: 28387960
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chronic polytherapy after myocardial infarction: the trade-off between hospital and community-based providers in determining adherence to medication.
    Di Martino M; Alagna M; Lallo A; Gilmore KJ; Francesconi P; Profili F; Scondotto S; Fantaci G; Trifirò G; Isgrò V; Davoli M; Fusco D
    BMC Cardiovasc Disord; 2021 Apr; 21(1):180. PubMed ID: 33853534
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of evidence-based therapy for the secondary prevention of acute coronary syndromes in Malaysian practice.
    Kassab YW; Hassan Y; Aziz NA; Akram H; Ismail O
    J Eval Clin Pract; 2013 Aug; 19(4):658-63. PubMed ID: 22845427
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Trends in adherence to secondary prevention medications in elderly post-myocardial infarction patients.
    Choudhry NK; Setoguchi S; Levin R; Winkelmayer WC; Shrank WH
    Pharmacoepidemiol Drug Saf; 2008 Dec; 17(12):1189-96. PubMed ID: 18956426
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Variation in initiating secondary prevention after myocardial infarction by hospitals and physicians, 1997 through 2004.
    Margulis AV; Choudhry NK; Dormuth CR; Schneeweiss S
    Pharmacoepidemiol Drug Saf; 2011 Oct; 20(10):1088-97. PubMed ID: 21538672
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Should all patients be treated with an angiotensin-converting enzyme inhibitor after coronary artery bypass graft surgery? The impact of angiotensin-converting enzyme inhibitors, statins, and β-blockers after coronary artery bypass graft surgery.
    Kalavrouziotis D; Buth KJ; Cox JL; Baskett RJ
    Am Heart J; 2011 Nov; 162(5):836-43. PubMed ID: 22093199
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Changes in prevalence of and prescribing for ischaemic heart disease in Ireland 1990-2002.
    Bennett K; Johnson H; Dack P; Shelley E; Feely J
    Ir J Med Sci; 2005; 174(3):4-8. PubMed ID: 16285330
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Utilization of evidence-based therapy for the secondary prevention of acute coronary syndromes in Australian practice.
    Vermeer NS; Bajorek BV
    J Clin Pharm Ther; 2008 Dec; 33(6):591-601. PubMed ID: 19138236
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Practice patterns and trends in the use of medical therapy in patients undergoing percutaneous coronary intervention in Ontario.
    Garg P; Wijeysundera HC; Yun L; Cantor WJ; Ko DT
    J Am Heart Assoc; 2014 Aug; 3(4):. PubMed ID: 25122664
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Does pharmacologic treatment in patients with established coronary artery disease and diabetes fulfil guideline recommended targets? A report from the EUROASPIRE III cross-sectional study.
    Gyberg V; Kotseva K; Dallongeville J; Backer GD; Mellbin L; Rydén L; Wood D; Bacquer DD;
    Eur J Prev Cardiol; 2015 Jun; 22(6):753-61. PubMed ID: 24691153
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Secondary prevention following coronary artery bypass grafting has improved but remains sub-optimal: the need for targeted follow-up.
    Turley AJ; Roberts AP; Morley R; Thornley AR; Owens WA; de Belder MA
    Interact Cardiovasc Thorac Surg; 2008 Apr; 7(2):231-4. PubMed ID: 18234766
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Socioeconomic Factors, Secondary Prevention Medication, and Long-Term Survival After Coronary Artery Bypass Grafting: A Population-Based Cohort Study From the SWEDEHEART Registry.
    Nielsen SJ; Karlsson M; Björklund E; Martinsson A; Hansson EC; Malm CJ; Pivodic A; Jeppsson A
    J Am Heart Assoc; 2020 Mar; 9(5):e015491. PubMed ID: 32114890
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Regional and practice variation in adherence to guideline recommendations for secondary and primary prevention among outpatients with atherothrombosis or risk factors in the United States: a report from the REACH Registry.
    Kumar A; Fonarow GC; Eagle KA; Hirsch AT; Califf RM; Alberts MJ; Boden WE; Steg PG; Shao M; Bhatt DL; Cannon CP;
    Crit Pathw Cardiol; 2009 Sep; 8(3):104-11. PubMed ID: 19726929
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Evolution of secondary prevention medication prescriptions after myocardial revascularisation: the ANCOR survey].
    Jullien G; Mosnier M; Danchin N
    Ann Cardiol Angeiol (Paris); 2005 Aug; 54(4):184-9. PubMed ID: 16104618
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Variations in coronary artery disease secondary prevention prescriptions among outpatient cardiology practices: insights from the NCDR (National Cardiovascular Data Registry).
    Maddox TM; Chan PS; Spertus JA; Tang F; Jones P; Ho PM; Bradley SM; Tsai TT; Bhatt DL; Peterson PN
    J Am Coll Cardiol; 2014 Feb; 63(6):539-46. PubMed ID: 24184238
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term adherence with cardiovascular drug regimens.
    Kulkarni SP; Alexander KP; Lytle B; Heiss G; Peterson ED
    Am Heart J; 2006 Jan; 151(1):185-91. PubMed ID: 16368315
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interventions to improve guideline compliance following coronary artery bypass grafting.
    Yam FK; Akers WS; Ferraris VA; Smith K; Ramaiah C; Camp P; Flynn JD
    Surgery; 2006 Oct; 140(4):541-7; discussion 547-52. PubMed ID: 17011901
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Secondary prevention of coronary artery disease in contemporary clinical practice.
    Jankowski P; Czarnecka D; Wolfshaut-Wolak R; Łysek R; Łukaszewska A; Bogacki P; Grodecki J; Mirek-Bryniarska E; Nessler J; Podolec P; Kawecka-Jaszcz K; Pająk A
    Cardiol J; 2015; 22(2):219-26. PubMed ID: 25299500
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patterns of prescription antihypertensive drug utilization and adherence to treatment guidelines in the city of Novi Sad.
    Tomas A; Tomić Z; Milijasević B; Ban M; Horvat O; Vukmirović S; Sabo A
    Vojnosanit Pregl; 2016 Jun; 73(6):531-7. PubMed ID: 27498444
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.